BRIEF-Cormedix Therapeutics Announces Preliminary Fourth Quarter And Full Year 2025 Results
Reuters01-08
BRIEF-Cormedix <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Preliminary Fourth Quarter And Full Year 2025 Results Jan 8 (Reuters) - CorMedix Inc CRMD.O:
CORMEDIX THERAPEUTICS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND PROVIDES BUSINESS UPDATES
Q4 2025 UNAUDITED NET REVENUE ABOUT $127 MILLION
EXPECTS Q4 ADJUSTED EBITDA BETWEEN $77 MILLION AND $81 MILLION
INTRODUCES FY 2026 REVENUE GUIDANCE $300-$320 MILLION
ESTIMATES FULL-YEAR 2027 DEFENCATH SALES IN RANGE OF $100 MILLION TO $140 MILLION
SEE FY 2026 OPERATING EXPENSES OF $145 MILLION TO $160 MILLION, EXCLUDING NON-CASH ITEMS AND ONE-TIME EXPENSES
ESTIMATES FY 2026 ADJUSTED EBITDA IN RANGE OF $100 MILLION TO $125 MILLION
FY2026 REVENUE VIEW $437.3 MILLION -- LSEG IBES DATA
Q4 REVENUE VIEW $127.5 MILLION -- LSEG IBES DATA
Source text: ID:nGNXc43vHb
Further company coverage: CRMD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
